Subcutaneous Drug Delivery Market expected to reach USD 56.503 billion by 2030

Subcutaneous Drug Delivery Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the subcutaneous drug delivery market will expand from USD 41.704 billion in 2025 to USD 56.503 billion in 2030 at a CAGR of 6.26% during the forecast period.

These systems offer patients greater convenience and accurate dosing, which reduces hospital visits for chronic illness management and fills major gaps in chronic disease management. Another important aspect contributing to the demand for subcutaneous drug delivery devices is the increase in the elderly population, as advanced age leads to a higher vulnerability to chronic diseases like diabetes, chronic obstructive pulmonary disease, various respiratory infections, asthma, and heart disease. Worldwide health data confirms that this age group, especially people older than 65, suffers the most from these conditions.

The demand for advanced minimally invasive solutions has caused an increase in the market for subcutaneous drug delivery devices. The rising incidences of chronic conditions such as cardiovascular diseases and diabetes, alongside the development of biological drugs, have modernized the healthcare landscape. The use of drug-device delivery systems such as prefilled syringes and autoinjectors represents a promising advancement in patient care and a reduction in healthcare costs.

Subcutaneous Drug Delivery Market Report Highlights

• The pen injectable segment is estimated to attain a greater market share by 2030 in the product type segment. The segment is predicted to grow primarily due to the ease of use and high portability, along with a decrease in the error in designing. Moreover, the high adoption rate of this product is for chronic disease management, such as in diabetes.
• The oncology segment is the fastest-growing segment in the application of the global subcutaneous drug delivery. The rise in incidence of cancer, which leads to demand for chemotherapy and biologics, and the use of wearables to extend the drug delivery, is also promoting the market. This method assists patients with cancer in decreasing hospital visits, which also contributes to improving patient outcomes by offering patient-centered treatments.
• The hospital and clinics industry is the dominating segment in the market in the end-user segment during the forecasted period, driven by the increase in healthcare infrastructure globally, along with an increase in patients with chronic disorders. This segment has professionals who can easily integrate this treatment solution, while also the direct accessibility of the advanced treatment device also fuels the market.
• North America held the largest global subcutaneous drug delivery market share in the coming years. Due to the advanced healthcare systems, a strong focus on innovation, and modern technology, the North American region is expected to dominate the market share. North America benefits from a robust healthcare system, attributed to advanced medical institutions that provide superior treatment and a broad availability of advanced drug delivery devices. Furthermore, the region’s significant R&D funding not only supports continuous innovation but also promotes the development of subcutaneous drug delivery devices, which, alongside the innovations, support the expansion of the market.

Report Coverage:

Report Metric	Details
Subcutaneous Drug Delivery Market Size in 2025	US$41.704 billion
Subcutaneous Drug Delivery Market Size in 2030	US$56.503 billion
Growth Rate	CAGR of 6.26%
Drivers	Growing Prevalence of Chronic Diseases Increasing Shift Toward Self-Administration and Patient-Centric Care
Restraints	Stringent Regulatory Frameworks High Cost of Development and Manufacturing
Segmentation	Product Type Application End-Users Geography
List of Major Companies in the Subcutaneous Drug Delivery Market	Becton, Dickinson and Company Elcam Medical Group Unilife Corporation Insulet Corporation Eli Lilly and Company

Subcutaneous Drug Delivery Market Growth Drivers and Restraints

Growth Drivers:

• Growing Prevalence of Chronic Diseases: The rapid rise in chronic diseases like diabetes, cancer, and cardiovascular diseases globally is promoting the requirement for efficient and self-administered drug delivery solutions, which is boosting the market.
• Increasing Shift Toward Self-Administration and Patient-Centric Care: The growing demand among patients for home-based medication, along with minimally invasive treatment, is prompting the demand for subcutaneous drug delivery, especially among geriatric and chronic patients.

Restraints:

• Stringent Regulatory Frameworks: The requirement for extensive approval from regulatory bodies like the FDA demands documentation and clinical trials, which could delay the launch of the product while also increasing the cost, which could hamper the market.
• High Cost of Development and Manufacturing: The high upfront investment for the research and development and testing of the complex devices could limit the market growth, along with posing a barrier for new entrants in this market.

Subcutaneous Drug Delivery Market Key Development

• Clinical innovation: In June 2025, Sanofi announced its clinical device innovation, which is to administer sarclisa via an on-body injector. It is a subcutaneous administration for decreasing the treatment burden associated with a range of myeloma therapies. This is aimed at shortening the treatment time and offering more efficiency and safety than the already available injectable infusion.

Subcutaneous Drug Delivery Market Segmentation

Knowledge Sourcing Intelligence has segmented the subcutaneous drug delivery market based on product type, application, end-user, and region:

Subcutaneous Drug Delivery Market, By Product Type

• Prefilled syringes
• Pen injector
• Auto injectors
• Wearable injectors
• Needle-free Injectors

Subcutaneous Drug Delivery Market, By Application

• Diabetes
• Fertility
• Oncology
• Others

Subcutaneous Drug Delivery Market, By End-User

• Hospitals and Clinics
• Homecare Settings
• Ambulatory Surgical Centers

Subcutaneous Drug Delivery Market, By Region

• North America
  • USA
  • Canada
  • Mexico
• South America
  • Brazil
  • Argentina
  • Others
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Others
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

Subcutaneous Drug Delivery Market Key Players

• Gerresheimer AG
• Ypsomed AG
• Medtronic Plc
• Sanofi
• Novo Nordisk
• Becton, Dickinson and Company
• Elcam Medical Group
• Unilife Corporation
• Insulet Corporation
• Eli Lilly and Company